Eli Lilly made a significant strategic move by acquiring Centessa Pharmaceuticals for a total potential value of $7.8 billion, including an upfront payment of $38.00 per share (approximately $6.3 billion) and Contingent Value Rights of up to $9.00 per share (approximately $1.5 billion) tied to FDA approvals. This acquisition, which represents a 44% premium over Centessa's recent trading average, is centered on Centessa’s lead asset, cleminorexton (formerly ORX750), a highly selective orexin receptor 2 (OX2R) agonist designed to treat narcolepsy and other sleep-wake disorders. The deal positions Lilly to leverage its financial strength, primarily from its success in obesity and diabetes markets, to become a leader in neuroscience and sleep medicine.
The acquisition has been hailed by analysts as a "seminal event" that validates the orexin agonist class as a multibillion-dollar frontier in central nervous system (CNS) medicine. While Takeda has historically led in the orexin field, Lilly's entry transforms the competitive landscape into a "battle of the titans." The market for sleep disorders is projected to grow substantially, from $30.5 billion in 2025 to $78.6 billion in 2035. This deal marks Lilly's second-largest M&A, following its 2019 acquisition of Loxo Oncology for $8 billion.
The immediate beneficiaries include Centessa shareholders, who saw their holdings appreciate by nearly 50%. The acquisition also sparked a "sympathy rally" for other companies in the orexin space, with Alkermes, developing alixorexton, seeing its stock rise by 18% as it's viewed as a potential acquisition target. Conversely, established players like Jazz Pharmaceuticals, with its oxybate franchise, and Harmony Biosciences, with Wakix, face significant uncertainty as orexin agonists like cleminorexton are perceived as a superior therapeutic class, acting as a "master switch" for wakefulness without the need for nighttime dosing.
The timeline to this deal was rapid, with Centessa's cleminorexton showing promising Phase 2a results in the CRYSTAL-1 trial, demonstrating superior wakefulness and a once-daily oral dose without liver toxicity issues seen in earlier agonists. These strong results and preparations for Phase 3 trials made Centessa an attractive "bolt-on" acquisition. Takeda is also actively in the race with its OX2R agonist, oveporexton, which has shown improvements in daily functioning, cognitive function, and sleep symptoms in Type 1 narcolepsy during Phase 3 trials, with an FDA decision expected soon. Alkermes' alixorexton has also shown promise in improving wakefulness and reducing daytime sleepiness in narcolepsy type 2 patients.
